12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

EGP-437: Phase I started

EyeGate began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate 3 doses of EGP-437 delivered through iontophoresis using the company's...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >